NurExone Biologic is developing regenerative exosome-based therapies for CNS injuries. Our lead candidate, ExoPTEN, targets acute spinal cord and optic nerve injuries—multi-billion-dollar markets—with strong preclinical results. With Orphan Drug Designation, a U.S. subsidiary, and unique minimally invasive exosome delivery, NurExone stands apart in offering scalable, targeted solutions for several unmet clinical needs